Onyx Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ONYX PHARMS
ONYX PHARMS has one approved drug.
There are four US patents protecting ONYX PHARMS drugs.
There are one hundred and ninety-one patent family members on ONYX PHARMS drugs in forty-two countries and eighteen supplementary protection certificates in sixteen countries.
Summary for Onyx Pharms
| International Patents: | 191 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Onyx Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | Yes | RE47954*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | AP | RX | Yes | Yes | 9,493,582*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | Yes | 7,417,042*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Onyx Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | 8,207,127 | ⤷ Start Trial |
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | 8,207,127 | ⤷ Start Trial |
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | 7,232,818 | ⤷ Start Trial |
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | 8,207,127 | ⤷ Start Trial |
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | 8,129,346 | ⤷ Start Trial |
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | 8,207,126 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ONYX PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 60 mg/vial | ➤ Subscribe | 2016-07-20 |
| ➤ Subscribe | For Injection | 10 mg/vial | ➤ Subscribe | 2018-11-28 |
International Patents for Onyx Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 603739 | ⤷ Start Trial |
| Germany | 602005026556 | ⤷ Start Trial |
| Japan | 2008522981 | ⤷ Start Trial |
| Australia | 2012211349 | ⤷ Start Trial |
| Hong Kong | 1231491 | ⤷ Start Trial |
| European Patent Office | 1756079 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Onyx Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1781688 | 122016000032 | Germany | ⤷ Start Trial | PRODUCT NAME: CARFILZOMIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1060 20151119 |
| 1781688 | C20160008 00189 | Estonia | ⤷ Start Trial | PRODUCT NAME: KARFILSOMIIB;REG NO/DATE: EU/1/15/1060 23.11.2015 |
| 1781688 | C01781688/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: CARFILZOMIB; REGISTRATION NO/DATE: SWISSMEDIC 65690 23.11.2015 |
| 1781688 | 132016000047656 | Italy | ⤷ Start Trial | PRODUCT NAME: CARFILZOMIB OPZIONALMENTE IN FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE(KYPROLIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1060, 20151123 |
| 1781688 | 1690013-6 | Sweden | ⤷ Start Trial | PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/15/1060 20151123 |
| 1781688 | SPC/GB16/022 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/15/1060 20151123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
